The Cancer Quality Improvement Program (CQIP) reports annual quality and outcomes data to more than 1,500 cancer programs accredited by the American College of Surgeons (ACoS) Commission on Cancer (CoC) using the National Cancer Data Base (NCDB).

For each of the four reports below, our Cancer Program treated 100% of the cases appropriately based on the quality measures for their respective categories. In each category, our Cancer Program exceeded the state, region, and all other CoC programs.

**The quality measure is indicated below each of the tables**
BREAST, 2015, BCSRT: Breast radiation after breast conserving surgery (NQF 0219 - Accountability)

Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer. (CP3R data as of 02/15/2016)

<table>
<thead>
<tr>
<th>Performance Rate</th>
<th>My Program</th>
<th>My State (ID)</th>
<th>My Census Region (Mountain)</th>
<th>My ACS Division (Great West)</th>
<th>My CoC Program Type (CCCP)</th>
<th>All CoC Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Denominator</strong></td>
<td>26</td>
<td>299</td>
<td>2743</td>
<td>5194</td>
<td>24844</td>
<td>56406</td>
</tr>
<tr>
<td></td>
<td>(100.0,100.0)</td>
<td>(94.2,98.4)</td>
<td>(90.0,92.2)</td>
<td>(91.3,92.7)</td>
<td>(91.6,92.2)</td>
<td>(91.8,92.2)</td>
</tr>
<tr>
<td><strong>95% CI</strong></td>
<td>26</td>
<td>299</td>
<td>2743</td>
<td>5194</td>
<td>24844</td>
<td>56406</td>
</tr>
<tr>
<td></td>
<td>(100.0,100.0)</td>
<td>(94.2,98.4)</td>
<td>(90.0,92.2)</td>
<td>(91.3,92.7)</td>
<td>(91.6,92.2)</td>
<td>(91.8,92.2)</td>
</tr>
</tbody>
</table>
BREAST, 2015, HT: Adjuvant hormonal therapy for hormone receptor positive breast cancer (NQF 0220 - Accountability)

Tamoxifen or third generation Aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor positive breast cancer. (CP3R data as of 02/15/2018)

© American College of Surgeons 2018—Content cannot be reproduced or repurposed without written permission of the American College of Surgeons.
COLON, 2015, ACT: Adjuvant chemotherapy for lymph node positive colon cancer (NQF 0223 - Accountability)

Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer. (CP3R data as of 02/15/2018)

Performance Rate
- My Program: 100%
- My State: 95.1%
- My Census Region (Mountain): 88.9%
- My ACS Division (Great West): 91.2%
- My CoC Program Type (CCCP): 88.9%
- All CoC Programs: 88.8%

Denominator
- My Program: 4
- My State: 41
- My Census Region (Mountain): 395
- My ACS Division (Great West): 746
- My CoC Program Type (CCCP): 4441
- All CoC Programs: 9794

95% CI
- My Program: (100.0, 100.0)
- My State: (88.5, 100.0)
- My Census Region (Mountain): (85.8, 92.0)
- My ACS Division (Great West): (89.2, 93.2)
- My CoC Program Type (CCCP): (88.0, 89.8)
- All CoC Programs: (88.2, 89.4)
COLON, 2015, 12RL: At least 12 regional lymph nodes removed and pathologically examined for resected colon cancer (NQF 0225 - Quality Improvement)

At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer. (CP3R data as of 02/15/2018)